Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H4N4S.H2O |
| Molecular Weight | 170.192 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.S=C1NC=NC2=C1N=CN2
InChI
InChIKey=WFFQYWAAEWLHJC-UHFFFAOYSA-N
InChI=1S/C5H4N4S.H2O/c10-5-3-4(7-1-6-3)8-2-9-5;/h1-2H,(H2,6,7,8,9,10);1H2
| Molecular Formula | C5H4N4S |
| Molecular Weight | 152.177 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Mercaptopurine, marketed under the brand name Purinethol among others, is a medication used for cancer and autoimmune diseases. Mercaptopurine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to thioinosinic acid (TIMP). This intracellular nucleotide inhibits several reactions involving inosinic acid (IMP), including the conversion of IMP to xanthylic acid (XMP) and the conversion of IMP to adenylic acid (AMP) via adenylosuccinate (SAMP). In addition, 6-methylthioinosinate (MTIMP) is formed by the methylation of TIMP. Both TIMP and MTIMP have been reported to inhibit glutamine-5-phosphoribosylpyrophosphate amidotransferase, the first enzyme unique to the de novo pathway for purine ribonucleotide synthesis. Experiments indicate that radiolabeled mercaptopurine may be recovered from the DNA in the form of deoxythioguanosine. Some mercaptopurine is converted to nucleotide derivatives of 6-thioguanine (6-TG) by the sequential actions of inosinate (IMP) dehydrogenase and xanthylate (XMP) aminase, converting TIMP to thioguanylic acid (TGMP). PURINETHOL (mercaptopurine) is indicated for maintenance therapy of acute lymphatic
(lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this
agent depends upon the particular subclassification of acute lymphatic leukemia and the age of
the patient (pediatric or adult).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2362992 |
|||
Target ID: GO:0001516 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PURINETHOL Approved UseMercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine tablets are not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine tablets are not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors. Launch Date1953 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
74 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3470165 |
75 mg/m² single, intravenous dose: 75 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MERCAPTOPURINE ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
|
69.5 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9048271 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
MERCAPTOPURINE ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
200 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3470165 |
75 mg/m² single, intravenous dose: 75 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MERCAPTOPURINE ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
|
135.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9048271 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
MERCAPTOPURINE ANHYDROUS plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3470165 |
75 mg/m² single, intravenous dose: 75 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
MERCAPTOPURINE ANHYDROUS plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
81% |
MERCAPTOPURINE ANHYDROUS plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
100 mg 3 times / day multiple, oral Studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, 37 years Health Status: unhealthy Age Group: 37 years Sex: F Sources: |
Other AEs: Anorexia, Nausea... Other AEs: Anorexia Sources: Nausea Vomiting Myelosuppression Hepatic disease |
50 mg/m2/hour 1 times / 2 days multiple, intravenous Studied dose Dose: 50 mg/m2/hour, 1 times / 2 days Route: intravenous Route: multiple Dose: 50 mg/m2/hour, 1 times / 2 days Sources: |
unhealthy, Median age 9.5 years Health Status: unhealthy Age Group: Median age 9.5 years Sources: |
Other AEs: ALT increased, AST increased... Other AEs: ALT increased (grade 3) Sources: AST increased (grade 3) Bilirubin increased (grade 3) |
1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
Other AEs: Pancytopenia, Neutropenic fever... Other AEs: Pancytopenia (100%) Sources: Neutropenic fever (91%) Bacteremia (65%) Candidemia (13%) Cytomegalovirus infection (4%) Bleeding (4%) Nausea (100%) Mucosal ulceration (52%) Diarrhea (26%) Typhlitis (4%) Alopecia (100%) Peeling of hands & feet on soles (52%) Papular skin eruption (30%) Conjunctivitis (13%) Death (8%) |
1250 mg/m2 1 times / day multiple, intravenous Highest studied dose Dose: 1250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1250 mg/m2, 1 times / day Sources: |
unhealthy, age range 4 to 14 years Health Status: unhealthy Age Group: age range 4 to 14 years Sex: M+F Sources: |
|
50 mg/m2/hour 1 times / 3 weeks multiple, intravenous Studied dose Dose: 50 mg/m2/hour, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 50 mg/m2/hour, 1 times / 3 weeks Sources: |
unhealthy, median age 10 years Health Status: unhealthy Age Group: median age 10 years Sources: |
DLT: Mucositis... |
35 mg/m2 1 times / day multiple, parenteral MTD Dose: 35 mg/m2, 1 times / day Route: parenteral Route: multiple Dose: 35 mg/m2, 1 times / day Sources: |
unhealthy, median age 60 years Health Status: unhealthy Age Group: median age 60 years Sources: |
DLT: Neutropenia, Thrombocytopenia... Other AEs: Neutropenia, Hyperbilirubinaemia... Dose limiting toxicities: Neutropenia (grade 3, 12.5%) Other AEs:Thrombocytopenia (grade 3, 12.5%) Neutropenia (grade 2, 75%) Sources: Hyperbilirubinaemia (50%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Anorexia | 100 mg 3 times / day multiple, oral Studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, 37 years Health Status: unhealthy Age Group: 37 years Sex: F Sources: |
|
| Hepatic disease | 100 mg 3 times / day multiple, oral Studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, 37 years Health Status: unhealthy Age Group: 37 years Sex: F Sources: |
|
| Myelosuppression | 100 mg 3 times / day multiple, oral Studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, 37 years Health Status: unhealthy Age Group: 37 years Sex: F Sources: |
|
| Nausea | 100 mg 3 times / day multiple, oral Studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, 37 years Health Status: unhealthy Age Group: 37 years Sex: F Sources: |
|
| Vomiting | 100 mg 3 times / day multiple, oral Studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, 37 years Health Status: unhealthy Age Group: 37 years Sex: F Sources: |
|
| ALT increased | grade 3 | 50 mg/m2/hour 1 times / 2 days multiple, intravenous Studied dose Dose: 50 mg/m2/hour, 1 times / 2 days Route: intravenous Route: multiple Dose: 50 mg/m2/hour, 1 times / 2 days Sources: |
unhealthy, Median age 9.5 years Health Status: unhealthy Age Group: Median age 9.5 years Sources: |
| AST increased | grade 3 | 50 mg/m2/hour 1 times / 2 days multiple, intravenous Studied dose Dose: 50 mg/m2/hour, 1 times / 2 days Route: intravenous Route: multiple Dose: 50 mg/m2/hour, 1 times / 2 days Sources: |
unhealthy, Median age 9.5 years Health Status: unhealthy Age Group: Median age 9.5 years Sources: |
| Bilirubin increased | grade 3 | 50 mg/m2/hour 1 times / 2 days multiple, intravenous Studied dose Dose: 50 mg/m2/hour, 1 times / 2 days Route: intravenous Route: multiple Dose: 50 mg/m2/hour, 1 times / 2 days Sources: |
unhealthy, Median age 9.5 years Health Status: unhealthy Age Group: Median age 9.5 years Sources: |
| Alopecia | 100% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Nausea | 100% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Pancytopenia | 100% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Candidemia | 13% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Conjunctivitis | 13% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Diarrhea | 26% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Papular skin eruption | 30% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Bleeding | 4% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Cytomegalovirus infection | 4% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Typhlitis | 4% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Mucosal ulceration | 52% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Peeling of hands & feet on soles | 52% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Bacteremia | 65% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Death | 8% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Neutropenic fever | 91% | 1125 mg/m2 1 times / day multiple, intravenous Studied dose Dose: 1125 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 1125 mg/m2, 1 times / day Sources: |
unhealthy, age range 2 to 17 years Health Status: unhealthy Age Group: age range 2 to 17 years Sex: M+F Sources: |
| Mucositis | grade 3, 30% DLT |
50 mg/m2/hour 1 times / 3 weeks multiple, intravenous Studied dose Dose: 50 mg/m2/hour, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 50 mg/m2/hour, 1 times / 3 weeks Sources: |
unhealthy, median age 10 years Health Status: unhealthy Age Group: median age 10 years Sources: |
| Hyperbilirubinaemia | 50% | 35 mg/m2 1 times / day multiple, parenteral MTD Dose: 35 mg/m2, 1 times / day Route: parenteral Route: multiple Dose: 35 mg/m2, 1 times / day Sources: |
unhealthy, median age 60 years Health Status: unhealthy Age Group: median age 60 years Sources: |
| Neutropenia | grade 2, 75% | 35 mg/m2 1 times / day multiple, parenteral MTD Dose: 35 mg/m2, 1 times / day Route: parenteral Route: multiple Dose: 35 mg/m2, 1 times / day Sources: |
unhealthy, median age 60 years Health Status: unhealthy Age Group: median age 60 years Sources: |
| Neutropenia | grade 3, 12.5% DLT |
35 mg/m2 1 times / day multiple, parenteral MTD Dose: 35 mg/m2, 1 times / day Route: parenteral Route: multiple Dose: 35 mg/m2, 1 times / day Sources: |
unhealthy, median age 60 years Health Status: unhealthy Age Group: median age 60 years Sources: |
| Thrombocytopenia | grade 3, 12.5% DLT |
35 mg/m2 1 times / day multiple, parenteral MTD Dose: 35 mg/m2, 1 times / day Route: parenteral Route: multiple Dose: 35 mg/m2, 1 times / day Sources: |
unhealthy, median age 60 years Health Status: unhealthy Age Group: median age 60 years Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no [IC50 133 uM] | ||||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
| no | ||||
| no | ||||
| no | ||||
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. | 2001-12 |
|
| Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children. | 2001-12 |
|
| Evolving medical therapies for ulcerative colitis. | 2001-12 |
|
| Diagnosis and treatment of perianal fistulas in Crohn disease. | 2001-11-20 |
|
| In vitro bioassays for anticancer drug screening: effects of cell concentration and other assay parameters on growth inhibitory activity. | 2001-11-08 |
|
| Management of fistulas in patients with Crohn's disease: antibiotic to antibody. | 2001-11 |
|
| Azathioprine for prevention of postoperative recurrence in Crohn's disease. | 2001-11 |
|
| Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. | 2001-11 |
|
| Pitfalls in the determination of mutant alleles of the thiopurine methyltransferase gene. | 2001-11 |
|
| Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. | 2001-11 |
|
| Azathioprine treatment and male fertility in inflammatory bowel disease. | 2001-11 |
|
| Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. | 2001-11 |
|
| Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. | 2001-11 |
|
| Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis. | 2001-10 |
|
| Managing the glucocorticoid dependent inflammatory bowel disease patient. | 2001-10 |
|
| A variant form of acute promyelocytic leukemia with marked myelofibrosis. | 2001-10 |
|
| 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. | 2001-10 |
|
| Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. | 2001-10 |
|
| Review article: the limitations of corticosteroid therapy in Crohn's disease. | 2001-10 |
|
| Development of obesity and neurochemical backing in aurothioglucose-treated mice. | 2001-09-17 |
|
| Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. | 2001-09-07 |
|
| Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia. | 2001-09 |
|
| Therapy-related CD7+ acute myeloid leukemia with trisomy 8 following acute monocytic leukemia. | 2001-09 |
|
| Use of azathioprine or 6-mercaptopurine for treatment of steroid-dependent lymphocytic and collagenous colitis. | 2001-09 |
|
| Neutropenia is not required for clinical remission during azathioprine therapy in inflammatory bowel disease. | 2001-09 |
|
| Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. | 2001-09 |
|
| Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. | 2001-08-01 |
|
| Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein. | 2001-08 |
|
| An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. | 2001-08 |
|
| [Metastatic Crohn's disease in childhood]. | 2001-08 |
|
| Glucocorticoids and IL-10, but not 6-MP, 5-ASA or sulfasalazine block endothelial expression of MAdCAM-1: implications for inflammatory bowel disease therapy. | 2001-08 |
|
| Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. | 2001-08 |
|
| Cyclosporine in ulcerative colitis: state of the art. | 2001-07-28 |
|
| Photoactivation of DNA thiobases as a potential novel therapeutic option. | 2001-07-24 |
|
| Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study. | 2001-07 |
|
| Prognostic impact of CD45 antigen expression in high-risk, childhood B-cell precursor acute lymphoblastic leukemia. | 2001-07 |
|
| Pneumococcal arthritis affects performance status in patients with chronic GVHD of the skin following allogeneic bone marrow transplantation. | 2001-07 |
|
| Repetitious appearance and disappearance of different kinds of clonal cytogenetic abnormalities after allogeneic bone marrow transplantation. | 2001-07 |
|
| Involvement of the NUP98 gene in a chromosomal translocation t(11;20)(p15;q11.2) in a patient with acute monocytic leukemia (FAB-M5b). | 2001-07 |
|
| Treatment of acute promyelocytic leukaemia using a combination of all-trans retinoic acid and chemotherapy. | 2001-07 |
|
| Azathioprine for atopic dermatitis. | 2001-07 |
|
| If at first you don't succeed...Try again? | 2001-07 |
|
| Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors. | 2001-07 |
|
| A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. | 2001-07 |
|
| New bioactive sulfated metabolites from the Mediterranean tunicate Sidnyum turbinatum. | 2001-02 |
|
| Pharmacogenetics: the therapeutic drug monitoring of the future? | 2001 |
|
| Pharmacokinetic considerations in the treatment of inflammatory bowel disease. | 2001 |
|
| Therapeutic drug monitoring of cytotoxic drugs. | 2001 |
|
| [Experimental study of radiosensitizing effect of analogs of purines and pyrimidine bases in cultured HeLa cells]. | 2001 |
|
| [Treatment of acute lymphoblastic leukemia in adults as an unsolved problem]. | 2001 |
Patents
Sample Use Guides
Usual Adult Dose for Intestinal Arterial Insufficiency
Initial Dosage:
Oral: 2.5 mg/kg of body weight per day (100 to 200 mg in the average adult). This dose may be continued daily for several weeks or more in some patients. If, after 4 weeks at this dosage, there is no clinical improvement and no definite evidence of leukocyte or platelet depression, the dosage may be increased up to 5 mg/kg daily. A dosage of 2.5 mg/kg per day may result in a rapid fall in leukocyte count within 1 to 2 weeks in some adults with acute lymphatic leukemia and high total leukocyte counts.
The total daily dosage may be given at one time. It is calculated to the nearest multiple of 25 mg.
Maintenance Therapy: Once a complete hematologic remission is obtained, maintenance therapy is considered essential. A usual daily maintenance dose of mercaptopurine is 1.5 to 2.5 mg/kg per day as a single dose. Mercaptopurine should rarely be relied upon as a single agent for the maintenance of remissions induced in acute leukemia.
Usual Adult Dose for Acute Lymphoblastic Leukemia
Initial Dosage:
Oral: 2.5 mg/kg of body weight per day (100 to 200 mg in the average adult). This dose may be continued daily for several weeks or more in some patients. If, after 4 weeks at this dosage, there is no clinical improvement and no definite evidence of leukocyte or platelet depression, the dosage may be increased up to 5 mg/kg daily. A dosage of 2.5 mg/kg per day may result in a rapid fall in leukocyte count within 1 to 2 weeks in some adults with acute lymphatic leukemia and high total leukocyte counts.
The total daily dosage may be given at one time. It is calculated to the nearest multiple of 25 mg.
Maintenance Therapy: Once a complete hematologic remission is obtained, maintenance therapy is considered essential. A usual daily maintenance dose of mercaptopurine is 1.5 to 2.5 mg/kg per day as a single dose. Mercaptopurine should rarely be relied upon as a single agent for the maintenance of remissions induced in acute leukemia.
Usual Adult Dose for Crohn's Disease - Acute
Oral: 1.0 to 1.5 mg/kg of body weight per day
Usual Adult Dose for Crohn's Disease - Maintenance
Oral: 1.0 to 1.5 mg/kg of body weight per day
Usual Adult Dose for Ulcerative Colitis - Maintenance
Oral: 1.0 to 1.5 mg/kg of body weight per day
Usual Adult Dose for Inflammatory Bowel Disease
Oral: 1.0 to 1.5 mg/kg of body weight per day
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:45 GMT 2025
by
admin
on
Mon Mar 31 17:50:45 GMT 2025
|
| Record UNII |
E7WED276I5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1556
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
||
|
WHO-ATC |
L01BB02
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
||
|
FDA ORPHAN DRUG |
373512
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
||
|
NDF-RT |
N0000175595
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/09/628
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
||
|
NCI_THESAURUS |
C574
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
||
|
WHO-VATC |
QL01BB02
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
XALUPRINE (AUTHORIZED: LEUKEMIA, LYMPHOID)
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
||
|
LIVERTOX |
NBK548546
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MERCAPTOPURINE
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
DTXSID9025538
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
50667
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
1708
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
SUB20430
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
1392002
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
m7208
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | Merck Index | ||
|
MERCAPTOPURINE
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | Description: A yellow, crystalline powder.Solubility: Practically insoluble in water and ether R; slightly soluble in ethanol (~750 g/l) TS; dissolves in solutions of alkali hydroxides. Category: Cytotoxic drug. Storage: Mercaptopurine should be kept in a well-closed container, protected from light.Additional information: CAUTION: Mercaptopurine must be handled with care, avoiding contact with the skin and inhalation of airborne particles.It melts at a temperature exceeding 308 ?C with decomposition. Requirements:Mercaptopurine contains not less than 97.0% and not more than the equivalent of 102.0% of C5H4N4S, calculated with reference to the anhydrous substance. | ||
|
759614
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
DB01033
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
103
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | RxNorm | ||
|
31822
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
E7WED276I5
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
7226
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
2724350
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
6112-76-1
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
CHEMBL1425
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
C195
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
100000085529
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
Mercaptopurine
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
755
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY | |||
|
E7WED276I5
Created by
admin on Mon Mar 31 17:50:45 GMT 2025 , Edited by admin on Mon Mar 31 17:50:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
ANHYDROUS->SOLVATE |
|
||
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|